A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Conditions:   Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting Intervention:   Drug: Dosing Interruption of Natalizumab Sponsors:   Berkovich, Regina MD, PhD Inc.;   Biogen;   Cedars-Sinai Medical Center Not yet recruiting

Source: ClinicalTrials.gov - August 7, 2019 Category: Research Source Type: clinical trials